Aspirin and the prevention of venous thromboembolism

New England Journal of Medicine

Volumn 366, Issue 21, 2012, Pages 2028-2030

  Becker, Richard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; PLACEBO; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; EDITORIAL; EMBOLISM PREVENTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LUNG EMBOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; RISK REDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84861385975     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1201911     Document Type: Editorial

References (10)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9. (Pubitemid 46563566)
2. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. [Erratum, BMJ 2002;324:141.]
4. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302.
5. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-67.
6. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012;10:136-44.
7. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8. (Pubitemid 27081901)
8. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7. [Erratum, N Engl J Med 1999;341:298.] (Pubitemid 29141050)
9. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9. (Pubitemid 32662124)
10. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence- based clinical practice guidelines. Chest 2012;141:Suppl(2): e419S-e4194S.